Patent US1807867A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4147797A Expired / Lapsed US ⏱️ 0.0 years remaining

Spiro-furanohydantoin derivatives

Assignee: Pfizer Inc
•
Filing: 1978-08-11
•
Granted: 1979-04-03
•
Expires: 1998-08-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract {PG,1 Novel spiro-furanohydantoin derivatives useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. The compounds include 2-methyl-spiro-{8 cyclohexa(b)furan-4,4{40 -imidazolidine{9 -2{40 ,5{40 -dione, 2-fluoro-spiro-{8 cyclohexa(b)furan-4,4{40 -imidazolidine{9 -2{40 ,5{40 -dione, 2-chloro-spiro-{8 cyclohexa(b)furan-4,4{40 -imidazolidine{9 -2{40 ,5{40 -dione, 2-bromo-spiro-{8 cyclohexa(b)furan-4,4{40 -imidazolidine{9 -2{40 ,5{40 -dione and spiro-{8 cyclohexa(b)furan-4,4{40 -imidazolidine{9 -2{40 ,5{40 -dione.

Inventors

  • 👤 Paul R. Kelbaugh
  • 👤 Reinhard Sarges

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-27 20:59
CPC Classifications
C; C07; C07D; C07D491/00; C07D491/02; C07D491/10; A; A61; A61P; A61P13/00; A61P13/02; A61P15/00; A61P25/00; A61P25/02; A61P27/00; A61P27/02; A61P27/12

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 22 words
A spiro-furanohydantoin compound of the formula ##STR3## or its pharmaceutically acceptable metal salt, wherein R is hydrogen, methyl, fluoro, chloro or bromo.
Claim 2
Dependent Claim 22 words
A spiro-furanohydantoin compound of the formula ##STR3## or its pharmaceutically acceptable metal salt, wherein R is hydrogen, methyl, fluoro, chloro or bromo.
Claim 3
Dependent Claim 34 words
A pharmaceutical composition of a command of claim 1 which comprises a pharmaceutical formulation of a pharmaceutically-acceptable carrier and a compound of claim 1 in an amount effective to prevent or alleviate diabetes-associated complications.
Claim 4
Dependent Claim 30 words
A method for the treatment of a diabetic host to prevent or alleviate diabetes-associated complications which comprises administering to the host an effective amount of a compound of claim 1.

References Cited (Backward Citations)

DE1135915B Cited
US3821383A Cited
US4117230A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-04-02 1982-10-02 1983-04-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-04-02 1986-10-02 1987-04-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-04-02 1990-10-02 1991-04-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag